Acute Myelogenous Leukemia clinical trials

Explore recruiting acute myelogenous leukemia clinical trials.

Recruiting acute myelogenous leukemia studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Acute Myelogenous Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2A, Open Label Dose Escalation and Cohort Expansion Study of Orally Administered CA-4948 (IRAK4i) as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Germany, Spain, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Monocentric phase 1 dose-escalation study of siltuximab in combination with idarubicin and cytarabine chemotherapy in patients with poor prognosis acute myelogenous leukemia (AML): SILTUXILAM

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment-naïve subjects with acute myelogenous leukemia who are ≥18 years of age and not eligible for standard induction therapy (VENAZA-5S PILOT TRIAL)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Acute Myelogenous Leukemia trials by city

Acute Myelogenous Leukemia clinical trials

Recruiting acute myelogenous leukemia studies right now

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Ziftomenib Maintenance Post Allo-HCT

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

Also recruiting in Europe

A Phase 1/2A, Open Label Dose Escalation and Cohort Expansion Study of Orally Administered CA-4948 (IRAK4i) as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Monocentric phase 1 dose-escalation study of siltuximab in combination with idarubicin and cytarabine chemotherapy in patients with poor prognosis acute myelogenous leukemia (AML): SILTUXILAM

An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment-naïve subjects with acute myelogenous leukemia who are ≥18 years of age and not eligible for standard induction therapy (VENAZA-5S PILOT TRIAL)

Acute Myelogenous Leukemia trials by city

Other conditions